Citigroup reaffirmed their buy rating on shares of AstraZeneca (LON:AZN) in a research report report published on Wednesday morning. The brokerage currently has a GBX 6,000 ($81.37) price target on the biopharmaceutical company’s stock.
Other equities research analysts also recently issued research reports about the company. Investec upped their target price on AstraZeneca from GBX 4,900 ($66.45) to GBX 5,500 ($74.59) and gave the stock a buy rating in a research report on Monday, November 6th. Berenberg Bank set a GBX 5,800 ($78.65) target price on AstraZeneca and gave the stock a buy rating in a research report on Tuesday, September 19th. Barclays set a GBX 6,300 ($85.44) target price on AstraZeneca and gave the stock a buy rating in a research report on Wednesday, September 13th. Jefferies Group reissued a hold rating and issued a GBX 5,100 ($69.16) price target on shares of AstraZeneca in a report on Monday, November 6th. Finally, JPMorgan Chase & Co. reissued a neutral rating on shares of AstraZeneca in a report on Friday, November 10th. Four equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of Hold and an average price target of GBX 5,200.82 ($70.53).
Shares of AstraZeneca (LON:AZN) remained flat at $GBX 5,132 ($69.60) during midday trading on Wednesday. The stock had a trading volume of 1,835,225 shares, compared to its average volume of 1,720,000. AstraZeneca has a 12 month low of GBX 4,136.50 ($56.10) and a 12 month high of GBX 5,520 ($74.86). The company has a market cap of $64,820.00 and a PE ratio of 2,479.23.
TRADEMARK VIOLATION NOTICE: “AstraZeneca’s (AZN) Buy Rating Reaffirmed at Citigroup” was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.thelincolnianonline.com/2018/01/13/astrazenecas-azn-buy-rating-reaffirmed-at-citigroup.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.